



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 28 Oct 2019 (#36)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices & News

- **[NOT-AG-20-003](#) NIA Intervention Testing Program (ITP) Announces Annual Call for Compounds to Test for Anti-Aging Activity in Mice.** The National Institute on Aging (NIA) Interventions Testing Program (ITP) was established to test compounds purported to extend lifespan and/or delay the onset of disease and disability. The NIA ITP tests such compounds in mice, using a variety of measured endpoints to assess the efficacy of interventions. There are three sites that perform the testing: University of Michigan, University of Texas Health Sciences Center-San Antonio & The Jackson Laboratory. It is anticipated that approximately 5 compounds will be accepted for study in 2021.
- **[NOT-HG-20-005](#) Notice of Intent to Publish a Funding Opportunity Announcement for Centers for Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry (U01 Clinical Trial Not Allowed)** The National Human Genome Research Institute intends to issue a Funding Opportunity Announcement (FOA) to solicit applications to support Centers for Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry. The FOA is expected to be published in January 2020.
- **[NOT-AR-20-005](#) Notice of Special Interest: Promoting research opportunities on HIV/AIDS in NIAMS.** The purpose of this announcement is to inform potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of an area of special interest in HIV/AIDS-associated comorbidities that are within the NIAMS mission. Related Announcements: [PA-19-056](#); [PA-19-053](#); [RFA-AR-20-001](#); [RFA-AR-20-002](#); [PA-18-591](#).
- **[NOT-CA-20-004](#) Notice of Special Interest (NOSI): Geospatial Approaches in Cancer Control and Population Sciences.** The National Cancer Institute (NCI) is interested in multilevel research that promotes geospatial approaches to advance cancer control and prevention research. Geospatial approaches include the use of location-based technologies such as geographic information systems (GIS), global positioning systems (GPS), other location-based technologies or may involve improved mapping techniques and applied spatial methodology.

1. NCMRR Early Career Research Award (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-042](#)

Type: R03

Application Due Date: March 30, 2020, March 30, 2021, March 30, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Center for Medical Rehabilitation Research (NCMRR) Early Career Research (ECR) Award (R03) is intended to support both basic and clinical research from rehabilitation scientists who are establishing independent research careers. The research must be focused on one or more of the areas within the biomedical and behavioral mission of NCMRR: pathophysiology and management of chronically injured nervous and musculoskeletal systems (including stroke, traumatic brain injury, spinal cord injury, and orthopedic conditions); repair and recovery of motor and cognitive function; functional plasticity, adaptation, and windows of opportunity for rehabilitative interventions; rehabilitative strategies involving pharmaceutical, stimulation, and neuroengineering approaches, exercise, motor training, and behavioral modifications; pediatric rehabilitation; secondary conditions associated with chronic disabilities; improved diagnosis, assessment, and outcome measures; and development of orthotics, prosthetics, and other assistive technologies and devices. The NCMRR ECR Award R03 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new technology. Irrespective of the type of project, the intent of the NCMRR ECR Award R03 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

Budget: The combined budget for direct costs for the entire project period may not exceed \$200,000. No more than \$100,000 in direct costs may be requested in any single year. The scope of the proposed project should determine the project period. The maximum period of support is 2 years.

2. Innovations to Foster Healthy Longevity in Low-Income Settings (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-20-027](#)

Type: R03

Application Due Date: February 3, 2020 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications for research and development to improve functioning and quality of life for the elderly, especially the disabled elderly, living in low- and middle-income countries (LMICs), or to improve functioning and quality of life for low-income, disabled, and isolated elderly living in high-income countries. Applications may address the needs of the elderly directly or indirectly by supporting family or other informal caregivers and service providers. Applications likely to have an impact on a large scale are encouraged.

Budget: NIA intends to commit \$750,000 in FY 2020 to fund 8-10 awards. Direct costs are limited to \$100,000 over a two-year period. No more than \$50,000 in direct costs may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

3. Limited Competition: Biospecimen Banks to Support NCI-National Clinical Trials Network (NCTN)(Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-002](#)

Type: U24

Application Due Date: December 17, 2019 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits renewal applications for biobanks that will support the following NCI clinical trial programs:

- The NCI National Clinical Trials Network ([NCTN](#)), and
- [NCI Community Oncology Research Program \(NCORP\)](#).

The NCTN Biospecimen Banks (also referred to as NCTN Biobanks) will be responsible for collecting, processing, storing, and distributing well-annotated human specimens from patients with cancer who are participating in NCI-funded NCTN Phase II-III and other clinical treatment trials. The main goal is to support the NCTN with the state-of-the-art banking infrastructure and operations including maintenance of up-to-date specimen inventory. The NCTN Biobanks will store trial biospecimens linked to high-quality clinical trial outcome data and distribute them to qualified investigators for approved studies for development and validation of biomarkers for cancer diagnosis, prognosis and prediction of responses to therapy. The NCTN Biobanks work in collaboration with NCTN Groups and Group Statistical and Data Management Centers as well as other affiliated institutions to ensure effective operations. Each Biobank needs to maintain association with one specific NCTN Group and needs to be endorsed in that role by the group leaders.

Budget: NCI intends to fund an estimate of five awards, corresponding to a total of \$17.23 million (total costs) for fiscal year 2020.

Application budgets must reflect the actual needs and scale of the proposed activities. Budget requests must not exceed \$3.0 million in direct costs per year. However, the high budget level would be expected only for a large, comprehensive banking operation and significantly lower budget requests are expected for smaller banking operations. Applicants should request a project period of 6 years.

4. Ethical Issues in Translational Science Research (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-TR-20-001](#)

Type: R01

Application Due Date: February 6, 2020, October 6, 2020, and October 6, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement is to support research to address ethical issues in translational science research. Collaboration between bioethicists, legal scholars, social scientists, and translational research scientists is encouraged. The focus is to develop knowledge to inform the ethical development, modification, or application of novel findings, technologies, and approaches to improve human health, including their impact on individuals, families, communities, and society.

Budget: National Center for Advancing Translational Sciences (NCATS) intends to commit total costs of \$500,000 in FY 2020, \$1,000,000 in FY 2021, and \$1,500,000 in FY2022. NCATS expects to fund up to 2 new awards in FY2020, 2 new awards in FY2021, and up to 2 new awards in FY2022 for a total of up to 6 new awards. Funds may not directly support any clinical trials beyond phase IIB with exception of Phase III clinical trials for treatment of rare diseases. See NOT-TR-18-025. Application budgets are limited to \$300,000 direct costs in any fiscal year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105